Darunavir (Prezista)

Table of Contents

- Darunavir Prezista Summary
- Drug Summary
- Key Clinical Trials
- Resistance
- Key Drug Interactions
- Citations
- Figures

Drug Summary

Darunavir is a potent, later-generation protease inhibitor that must be combined with a pharmacokinetic booster, either cobicistat or ritonavir. Boosted darunavir is an option for initial antiretroviral therapy, but now it is used more often as a common component of salvage regimens for treatment-experienced individuals. Darunavir has a unique resistance pathway and retains activity following the development of drug resistance with most other protease inhibitors, with a notable exception that virologic failure on fosamprenavir can result in cross resistance with darunavir. In addition, darunavir has a high barrier to resistance, and when patients taking darunavir develop virologic failure, darunavir-associated resistance mutations usually are not present. For treatment-naïve patients, ritonavir-boosted darunavir is dosed once daily; for treatment-experienced patients, the dosing of darunavir is determined by whether or not darunavir-associated mutations are present. If they are absent, ritonavir-boosted darunavir can be dosed once daily, but if darunavir-associated mutations are present, the dosing should be twice daily. The fixed-dose combination of darunavir-cobicistat should only be used when once daily darunavir dosing is appropriate. The primary disadvantages of darunavir include moderate gastrointestinal side effects, potential for drug interactions, and possible adverse reactions in individuals with history of severe sulfa allergy (darunavir contains a sulfonamide moiety).

Key Clinical Trials

Darunavir has been extensively studied in treatment-naïve and treatment-experienced individuals. In antiretroviral-naïve adults, a comparison of once-daily ritonavir-boosted darunavir with lopinavir-ritonavir (given once or twice-daily), each with tenofovir DF-emtricitabine, showed similar virologic efficacy between the two arms, except for the subset of participants with pre-treatment HIV RNA levels above 100,000 copies/mL, who achieved higher rates of virologic suppression with ritonavir-boosted darunavir [ARTEMIS]. In treatment-naïve individuals, a randomized comparison of once-daily ritonavir-boosted darunavir and once-daily dolutegravir, each with two NRTIs, showed that the darunavir arm was inferior, largely due to more side effects and treatment discontinuations [FLAMINGO]. In a trial of treatment-naïve individuals randomized to
ritonavir-boosted darunavir, ritonavir-boosted atazanavir, or raltegravir, each with tenofovir DF-emtricitabine, raltegravir achieved the best virologic outcomes, followed by boosted darunavir, and then boosted atazanavir [ARDENT]. Outcome differences in that trial were largely driven by tolerability. The combination tablet darunavir-cobicistat-tenofovir alafenamide-emtricitabine was shown to be an effective option for treatment-naive individuals AMBER, including for rapid initiation [DIAMOND], and as a switch strategy for certain treatment-experienced persons EMERALD.

In treatment-experienced individuals with multiclass drug resistance, twice-daily ritonavir-boosted darunavir was compared to other boosted protease inhibitors (each given with an optimized background regimen of NRTIs with or without enfuvirtide); boosted darunavir achieved statistically higher rates of virologic response [POWER 1 and 2]. A noncomparative trial that included individuals with virologic failure and multiclass drug resistance found high rates of virologic success with a salvage regimen that included ritonavir-boosted darunavir (given twice daily) plus raltegravir plus etravirine [TRIO]. In treatment-experienced persons with no darunavir-associated mutations but detectable HIV RNA while taking stable antiretroviral therapy, a randomized switch to either once-daily or twice-daily ritonavir-boosted darunavir plus NRTIs resulted in no statistically significant difference in rates of HIV RNA suppression at week 48 [ODIN].

Several studies demonstrated the efficacy of monotherapy with ritonavir-boosted darunavir as a simplification strategy in patients with previously suppressed HIV RNA levels on a standard three-drug regimen [MONO] and [MONET].

Resistance

For a listing of the most common clinically significant mutations associated with darunavir (DRV) resistance, see the PI Resistance Notes on the Stanford University HIV Drug Resistance Database.

Key Drug Interactions

For complete information on darunavir-related drug interactions, see the Drug Interactions section in the Darunavir (Prezista) Prescribing Information.

Citations


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


[PubMed Abstract]


darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the


[PubMed Abstract] -


antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised


[PubMed Abstract] -


Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir,


[PubMed Abstract] -

17. Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or
tenofvir-emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the


[PubMed Abstract] -


transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with


[PubMed Abstract] -


monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial,


[PubMed Abstract] -


on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acquir Immune Defic


[PubMed Abstract] -

21. Girard PM, Campbell TB, Grinsztejn B, et al. Pooled week 96 results of the phase III DUET-1 and

DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special


[PubMed Abstract] -

22. Gruber VA, Rainey PM, Moody DE, et al. Interactions between buprenorphine and the protease


[PubMed Abstract] -


vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoprophil Fumarate and Emtricitabine

or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral


[PubMed Abstract] -


Figures

Figure 1. darunavir-prezista_800mg-tablet